Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 29:7:285-99.
doi: 10.2147/CCID.S53119. eCollection 2014.

Management of hyperhidrosis

Anna-Bianca Stashak  1 , Jerry D Brewer  2
Affiliations
Review

Management of hyperhidrosis

Anna-Bianca Stashak et al. Clin Cosmet Investig Dermatol. .

Abstract

Primary hyperhidrosis (HH), a condition of sweating in excess of thermoregulatory requirements, affects nearly 3% of the US population and carries significant emotional and psychosocial implications. Unlike secondary HH, primary HH is not associated with an identifiable underlying pathology. Our limited understanding of the precise pathophysiologic mechanism for HH makes its treatment particularly frustrating. However, a wide array of interventions for the treatment of HH have been implemented throughout the world. Herein, we discuss the most extensively studied therapeutic options for primary HH, including systemic oxybutynin, botulinum toxin injections, skin excision, liposuction-curettage, and sympathotomy/sympathectomy. We conclude with a discussion of possible future therapies for HH, including the applications of laser, microwave, and ultrasound technologies.

Keywords: botulinum toxin; eccrine ducts; laser; primary hyperhidrosis; secondary hyperhidrosis; surgery.

PubMed Disclaimer

References

    1. Naumann M, Lowe NJ, Kumar CR, Hamm H, Group HCI. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol. 2003;139(6):731–736. - PubMed
    1. Ram R, Lowe NJ, Yamauchi PS. Current and emerging therapeutic modalities for hyperhidrosis, part 1: conservative and noninvasive treatments. Cutis. 2007;79(3):211–217. - PubMed
    1. Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004;51(2):241–248. - PubMed
    1. Slingluff CL, Petroni GR, Molhoek KR, et al. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47) Clin Cancer Res. 2013;19(13):3611–3620. - PMC - PubMed
    1. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–286. - PubMed

LinkOut - more resources